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Abstract
Background: Neuropilin is a transmembrane receptor for vascular endothelial growth factor (VEGF) and is
expressed in normal endothelial cells and upregulated in cancer cells. Neuropilin-1 (NRP-1) has been shown to
promote tumour cell migration and survival in colon cancer in response to VEGF binding. The expression profiles
of neuropilins, associated co-receptors and known ligands have been mapped in three colorectal cell lines: Caco-2,
HCT116 & HT29. We have previously shown that butyrate, a naturally occurring histone deacetylase inhibitor
(HDACi) produced by fermentation of fibre in the colon, causes apoptosis of colon cancer cell lines.
Results: Here we demonstrate that butyrate down-regulates NRP-1 and VEGF at the mRNA and protein level in
colorectal cancer cell lines. NRP-1 is a known transcriptional target of Sp1, whose activity is regulated by
acetylation. NRP-1 down-regulation by butyrate was associated with decreased binding affinity of Sp1 for canonical
Sp-binding sites in the NRP-1 promoter. siRNA-mediated knock-down of Sp1 implied that Sp1 may have strong
DNA binding activity but weak transactivation potential.
Conclusion: The downregulation of the key apoptotic and angiogenesis regulator NRP-1 by butyrate suggests a
novel contributory mechanism to the chemopreventive effect of dietary fibre.
Background
Fermentation of fibre in the colon leads to production
of short-chain fatty acids (SCFA) including butyrate.
Butyrate has been implicated in cellular homeostasis of
the normal colonic mucosa, and this is thought to
underwrite the chemoprotective effect of fibre [1].
In vitro studies indicate that butyrate causes cell cycle
arrest, differentiation or apoptosis in a number of trans-
formed cell lines. These outcomes are mediated by buty-
rate’s inhibition of histone deacetylases (HDACs).
Transcription factors Sp1 and Sp3 share canonical GC
boxes and are thought to bind with equivalent affinity.
Moreover, both Sp1 and Sp3 have been reported as
acetylated and are targets for HDAC1 and HDAC2 [2,3].
Butyrate has been shown to inhibit HDAC activity
thereby down-regulating Sp1 binding and up-regulating
Sp3 binding. This leads to an increase in p21 expression,
which ultimately causes cell cycle arrest [4]; and an
increase in Bak expression which ultimately causes
apoptosis [5]. Both events may contribute to the chemo-
preventive action of butyrate. In an accompanying
paper, we use a novel anti-acetyl-Sp1 antibody to show
that upregulation of p21, Bak and acetylation of Sp1
respond to the same subset of HDACi with highly simi-
lar EC50, implying a simple and causal relationship [6].
The vascular endothelial growth factor (VEGF) family
comprises members that share structural homology and
have been linked to cancer angiogenesis, metastasis and
survival [7]. VEGF signalling on endothelial cells is
mediated by three tyrosine kinase receptors VEGFR1-3
[8]. However, the Neuropilin (NRP) family of 130-140
kDa transmembrane glycoprotein receptors has recently
been implicated in both VEGF-mediated angiogenesis
[9] and colon cancer cell survival [10]. NRP-1 and NRP2
are non-tyrosine kinase receptors that bind with specific
members of the VEGF family: NRP-1 binds VEGF165,
VEGF-B, VEGF-E and placenta growth factor-2; whereas
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[11]. NRP-1 is expressed in morphologically normal
colonic epithelium [12] and is commonly over-expressed
in human colon cancer where it correlates with
advanced grade, metastatic potential [12], and decreased
patient survival [13]. Cloning of the promoter region of
NRP-1 demonstrated the presence of an AP-1, a
CCAAT box and two Sp1 elements all of which contri-
bute to induced promoter activity [14]. However, as yet
it is not clear which of these elements is involved in the
up-regulation of NRP-1 expression in colon cancer.
Patient data indicate that colorectal tumours with
increased NRP-1 expression have a greater incidence of
metastases, increased proliferation index and reduced
numbers of apoptotic cancer cells than tumours with
low NRP-1 staining [13] suggesting that NRP-1 may
protect colon cancer cells from apoptosis. Interestingly
siRNA-induced down-regulation of NRP-1 has been
shown to increase sensitivity to chemotherapy by induc-
tion of apoptosis [15] suggesting that down-regulation
of NRP-1 may have therapeutic potential. Therefore,
modification of Sp family activity by butyrate and the
potential of NRP-1 as an Sp1 target led us to investigate
the ability of butyrate to modulate NRP-1 expression,
with a view to providing an alternative therapy or che-
mopreventive strategy for colon cancer.
Results
Profile of angiogenic factors and their receptors mRNA
expression in human colon cancer cell lines
The mRNA expression of VEGF isoforms, PDGF, HGF
and their receptors were determined in three colon can-
cer cell lines (HCT116, HT29 and Caco-2) by RT-PCR.
HDMECs (human dermal microvascular endothelial
cell) and universal cDNA were used as positive or nega-
tive controls (Figure 1). All cell lines expressed VEGFA
and VEGFB but not VEGFC. VEGFR1 was undetectable,
whereas VEGFR2 and VEGFR3 showed a weak or nega-
tive expression in the cell lines. NRP-1 was expressed
equally in all tested cell lines; however, NRP-2 expres-
sion varied between lines: it was expressed strongly in
Caco-2, weakly in HC116 and not expressed in HT29
cells. The NRP-1 co-receptor HGFR was strongly and
equally expressed in all lines, but its principal ligand
(HGF) was not expressed. Contrastingly both isoforms
of the PDGF ligand, but neither of its receptors were
expressed.
Butyrate downregulates NRP-1 at the mRNA and
protein levels
Preliminary data from a microarray analysis of genes
altered in response to butyrate in the cell lines used
indicated that NRP-1 expression was reduced (See
Additional file 1: Fig S1). Therefore a concentration
range of butyrate treatment was undertaken in three
colon cancer cell lines (HCT116, HT29 and Caco-2).
These lines represent a range of cancer types: HCT116
reportedly has a wild-type p53 response, but is mis-
match repair deficient, whereas both HT29 and Caco-2
are p53 deficient chromosome instable lines, and Caco-
2 retains differentiation potential. There was a clear
concentration-response effect of incremental treatment
with butyrate between 0 and 20 mM at the mRNA level
(Figure 2A) in all three cell lines. The alteration was
pronounced and statistically significant from 0.5 mM.
Immunoblotting in HCT116 cells was therefore under-
taken in order to confirm that the reduction in NRP-1
mRNA expression would translate to a change in pro-
tein expression (Figure 2B). A decrease in NRP-1 pro-
tein expression was noticeable at 5 mM butyrate and
significant in three independent repeats above 10 mM.
Taken together these data show that HCT116, HT29 or
Caco-2 cells exposed to butyrate will down-regulate
NRP-1 expression through decreased mRNA production
leading to reduction in protein levels.
To validate further, we undertook a high-content analy-
sis (HCA) of NRP-1 in HCT116 cells (Figure 2C &2D).
The distribution of NRP-1 was very heterogenous (see
also Additional file 1: Fig S2 for larger image) and was
Figure 1 mRNA expression of angiogenesis factors and their
receptors in three human colon cancer cell lines. VEGFA, VEGFB,
VEGFC, VEGFR1, VEGFR2, VEGFR3, NRP-1, NRP2, PDGFA, PDGFB,
PDGFRa, PDGFRb, HGF and HGFR mRNA were extracted using Trizol
and expression was determined by RT-PCR in Caco-2, HCT116, HT29
cell lines. HDMEC and universal cDNA were used as positive or
negative controls respectively.
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Page 2 of 13Figure 2 Butyrate down-regulates NRP-1 at the mRNA and protein level. HCT116, HT29 and Caco-2 cell lines were treated for 20 hours
with media supplemented with increasing concentrations of butyrate. (A) NRP-1 mRNA expression in all three cell lines is significantly reduced
when treated with butyrate compared to untreated cells. (B) The level of NRP-1 protein was measured in samples from cells treated with the
same range of butyrate concentrations (Bi) shows typical immunoblot for NRP-1 and actin loading control. Intensity was quantitated, normalized
to actin and expressed as a proportion of the untreated control (Bii). Reduction was significant at 10 mM and above. *P < 0.05, **P < 0.01,
***P < 0.001. (C) HCT116 cells were grown in 96 well plates, fixed and stained for NRP-1 following butyrate treatment. Panels I & ii show sample
images acquired during HCA of the untreated control sample with distinct distributions of NRP-1; (D) Amount of NRP-1 immunofluorescence in
cells was quantified by HCA following treatment with butyrate. Significance of decrease across three experiments was determined by ANOVA
with p-values inset in the figures.
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Page 3 of 13variously observed as periplasmic, perinuclear and pan-
cytosolic. The levels of NRP-1 in cells were quantified
by HCA as total NRP-1 (Figure 2D). Following butyrate
treatment a decrease in level of NRP-1 cross-reactivity
was seen in the cell as a whole consistent with the find-
ings from immunoblotting and qRT-PCR. The function-
ality of HCA was used to assess whether subcellular
distribution was altered however no profound alterations
were observed over and above the downgregulation (see
Additional file 1: Fig S3).
Regulation of NRP-1 by transcription factors Sp1 and Sp3
NRP-1 has previously been shown to be regulated at the
transcriptional level by Sp1 and two Sp1 functional con-
sensus sequences occur in the NRP-1 promoter [14].
Our data on butyrate-mediated dysregulation of Bak
and p21 suggest alteration in Sp1 binding affinity
mediated by increased acetylation of Sp1 is a key event
[5]. We therefore investigated the affinity of Sp1 for the
NRP-1 promoter following treatments with butyrate
known to affect NRP-1 expression. A previously
described [5] modified EMSA (WeMSA) was employed
to assess alteration in binding of Sp1 to the two puta-
tive Sp1 binding sites in the NRP-1 promoter, SpA and
SpB (Figure 3A). Increased concentrations of butyrate
from 0-20 mM led to decreased affinity of Sp1 for these
two target sequences (Figure 3Bi). Nuclear extracts used
in binding assays were immunoprobed for Sp1 to con-
firm that Sp1 levels remained constant before and after
treatment with butyrate, indicating that the observed
reduction in Sp1 cross-reaction is attributable to
reduced DNA-binding affinity of Sp1 (Figure 3Bii).
Quantification of three independent repeats of this
experiment showed that reduction in binding affinity is
progressive and starts at 0.5 mM. The reduction in
binding is significant for both target sites following
treatment with concentrations of butyrate of 5 mM and
above (Figure 3Biii).
In certain cellular contexts and at several genes dysre-
gulated by butyrate, Sp1 appears to be displaced by Sp3
following treatment. We therefore examined the effect
of butyrate on binding of both short (S) and long (L)
forms of Sp3 at the SpA and SpB binding sites. Both
Sp3L and Sp3S bound to SpA and SpB. Following buty-
rate treatment binding to both sequences by Sp3S was
reduced significantly, whereas Sp3L binding remained
essentially constant (Figure 3Ci). Quantification of three
independent repeats showed that the reduction in Sp3S
binding to both SpA and SpB was significant at 5 mM
and above (Figure 3Ciii). Nuclear extracts were also
immunoprobed for Sp3 to verify that the observed
mobility shift changes were due to altered binding affi-
nity and not attributable to altered expression of Sp3
(Figure 3Cii).
Taken together these data imply that down-regulation
of NRP-1 transcription may primarily be through
reduced Sp1 and Sp3 binding.
Conservation of NRP-1 response to HDAC inhibition
In order to assess whether the response of NRP-1 expres-
sion to butyrate was mediated through butyrate’sa c t i o n
as an inhibitor of HDACs, and potentially through acety-
lation and inhibition of Sp1, we undertook a concentra-
tion-response study using a high-content analysis
strategy. HCT116 cells were treated with increasing con-
centrations of butyrate or one of four hydroxamic acids,
two of which we have previously shown to induce Sp1
acetylation (oxamflatin and scriptaid), and two with mini-
mal Sp1-acetylating potential (CHAHA and APHA
compound 8). Compounds were used over a 2-log con-
centration range around the known EC50 for Sp1 acetyla-
tion [6]. Following analysis it was shown that all the
HDAC inhibitory compounds reduced NRP-1 expression
by around 50% (Fig 4). Butyrate, oxamflatin and scriptaid
all induced Sp1 acetylation, but in accordance with our
previous study (ibid.) the level of Sp1 acetylation follow-
ing CHAHA and APHA was much lower. Inspection of
the concentration-response curves suggested that the
EC50s for NRP-1 were consistently lower that the EC50s
for Sp1 acetylation. These data suggest that Sp1 acetyla-
tion alone cannot account for the alteration in NRP-1
activity.
Role of Sp1/3 and HDACs in NRP-1 regulation
In order further to distinguish the specific roles of Sp1,
Sp3 in regulation of Sp1, we undertook a series of
siRNA knock-down studies. HCT116 cells were trans-
fected with siRNA to Sp1 and Sp3 and protein lysates
analysed by western blot for efficacy and specificity of
knock-down (Figure 5A). Reduction in Sp1 and Sp3
levels was substantial, but appeared to cause reduction
in cell number (data not shown), perhaps reflecting an
essential role of these transcription factors in cell viabi-
lity. HCT116 cells were transfected with siRNAs against
Sp1 and Sp3 (Ambion ID: 143158 and 115336 respec-
tively). 48 hrs post transfection cells were harvested to
confirm knockdown at the protein level. Duplicate plates
were treated with 0 or 10 mM butyrate for 18 hr. Total
RNA was harvested 72 hrs post transfection. Relative
NRP-1 expression levels were quantified using Qiagen
qRT-PCR gene expression assays to establish the down-
stream effect of Sp1 or Sp3 knock-down on NRP-1
expression in the presence and absence of butyrate
(Figure 5B). Use of a student’s t-test demonstrated that
knock-down of Sp1 or Sp3 resulted in significant up-
regulation of NRP-1 both in the presence and absence
of butyrate (P < 0.05). These data are consistent with a
model for Sp1 acting as a weak transcriptional activator
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Page 4 of 13Figure 3 Sp1 has reduced affinity for the NRP-1 promoter after butyrate treatment. The organisation of the NRP-1 promoter region,
specifically the two distinct Sp consensus sequences SpA and SpB, is shown (A). Nuclear extracts from HCT116 cells treated with 0-20 mM
butyrate, were used in a mobility shift assay (WeMSA, previously described [5]), using Sp1antibodies (Panels B) and Sp3 antibodies (Panels C) to
determine the binding activities at the two Sp sites. (Bi) Immunoblotting of Sp1 showed that binding activity to SpA and SpB elements was
reduced by butyrate in a concentration-dependent manner. (Bii) showed that immunoblotting of Sp1 from nuclear extracts used in binding
assays reveals the stable expression of Sp1 before and after treatment with butyrate. (Biii) Densitometry of WeMSA immunoblots indicated that
this reduction in binding is significant (*P < 0.05). (C) The same analyses using Sp3 immunoblots revealed that Sp3S binding was significantly
reduced at both SpA and SpB, whereas Sp3L binding remained constant before and after treatment (Panels Cii, Ciii, *P < 0.05).
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Page 5 of 13Figure 4 Analysis of response of NRP-1 to multiple HDAC inhibitors. The extent of the concomitant response of Sp1 acetylation and NRP-1
down- regulation was determined using a high-content analysis approach. HCT116 cells were treated for 24 hr with concentration ranges of 0-
20 mM sodium butyrate, 0-20 μM Oxamflatin, 0-20 μM Scriptaid, 0-20 μM APHA compound 8, 0-20 μM CHAHA. Cells were stained for acetyl-Sp1
and NRP-1 as described in the methods section. Levels of protein are expressed in terms of fluorophore fluorescence relative to that observed in
untreated cells, left column shows fluorescence for acetyl-Sp1 and right column for NRP-1.
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Page 6 of 13but with high affinity for DNA, with Sp3 acting as a
low-affinity strong transcriptional activator. However the
increase in NRP-1 mRNA observed following Sp1 or
Sp3 knockdown was not sufficient enough to restore
levels to those observed before butyrate treatment. This
observation suggests that other acetylation events as a
result of butyrate treatment may play a role in butyrate-
mediated suppression of NRP-1 mRNA expression.
Butyrate downregulates VEGF at the mRNA and
protein levels
Butyrate has been shown to affect VEGF expression [16]
in certain cellular contexts. To establish the consistency,
level and direction of this effect in our panel of cell
lines, RNA, protein and supernatant were collected from
HCT116, HT29 or Caco-2 cells treated with 0-20 mM
butyrate for 20 hours and analyzed by qRT-PCR,
Figure 5 siRNA reveals the contribution of Sp1, Sp3 and HDACs1, 2, 3 to NRP-1 expression. Sp1 and Sp3 siRNA were screened for
functionality and a single siRNA to each transcription factor was selected for further study. (A) Efficacy and specificity of Sp1 and Sp3 knock-
down were shown by immunoblotting protein extracts from transfections and controls 48 hr after transfection. (B) The levels of NRP-1 transcript
relative to negative siRNA transfected cells were determined by qRT-PCR using the comparative ΔΔCt method of quantification ns = no
significant difference * = P < 0.05, ** = P < 0.01 Student’s t-test compared to negative siRNA sample. n = 3 replicates. Error bars represent
mean ± s.e.
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Page 7 of 13immunoblotting or ELISA. In contrast to the results
with NRP-1, effects varied by cell line. A pronounced
and significant down regulation of VEGF mRNA was
seen in the HCT116 and Caco-2 cells, whereas there
appeared to be no effect in the HT29 cells (Figure 6A).
When the secreted protein levels from HCT116 were
measured by ELISA, they were significantly reduced at
all tested concentrations of butyrate (Fig 6Bi), although
this relationship appears biphasic when corrected for
cell mass (Fig 6Bii). This is probably due to the very low
numbers of cells at higher concentrations of butyrate
treatment causing a denominator effect. In contrast to
the mRNA and ELISA data, in the HCT116 cells the
total VEGF protein did not decrease in cells, but showed
a non-significant trend towards increase (Figure 6C).
VEGF levels and subcellular distribution were analysed
by HCA as described for NRP-1 (vide supra). Subcellu-
lar distribution of VEGF was more homogenous in the
cell population than NRP-1 (Figure 3Dii). Following
treatment with butyrate staining intensity increased with
a suggestion of a more punctuate distribution (Figure
3Diii, see arrows). Increase in cellular intensity of VEGF
was quantified by HCA and in agreement with data
from the western blotting. Data showing VEGF accumu-
lation were highly significant for all events. The func-
tionality of the HCA was used to assess whether
redistribution occurred internally for VEGF following
butyrate treatment, but no alterations were noted (Addi-
tional file 1: Fig S4).
Taken together these data suggest a reduction in
VEGF production and signalling by cells following buty-
rate treatment. We hypothesize that the apparent intra-
cellular increase in VEGF may be due to accumulation
owing to cessation of export and synthesis preceding
degradation of the protein.
Discussion
Neuropilin-1 was initially characterised as a receptor for
semaphorins which mediate neuronal cell guidance,
however, it has more recently been identified as an iso-
form-specific receptor for VEGF in endothelial cells.
Furthermore it is expressed in some tumour cells includ-
ing colon cancer. While it is known to augment angiogen-
esis through enhancing the binding of VEGF to VEGF-R2
on endothelial cells, it has also been shown to play an
essential role in autocrine anti-apoptotic signalling by
VEGF in NRP-1 positive breast cancer cells lacking VEGF-
R2 [17,18]. More recently NRP-1 has been shown to be
expressed in colon cancer [10] and inhibition of NRP-1 in
colon cancer cell lines using siRNA significantly increased
cancer cell apoptosis [13]. These data suggest that inhibi-
tion of NRP-1 may result in improved prognosis for colon
cancer patients, especially as high levels of NRP-1 expres-
sion correlated with poor patient survival [13].
Using a panel of tumour-derived lines with epithelial
phenotype, we established a profile of gene expression
for the families of VEGF ligands and receptors. There
was a general consistency in these lines of expression of
VEGF A and B, but not C, and little or no expression of
any of the classical VEGFR. HGF was not expressed
although its receptor was. Contrastingly, the PDGF
ligands, but not the receptors were expressed. These
data may suggest HGFR as a likely co-receptor with
NRP-1, especially as others have shown that this occurs
in pancreatic cancer cell lines [19]. However, it is possi-
b l et h a tp l e x i n sm a ya l s ob eb i n d i n gp a r t n e r sa n dt h e s e
have yet to be studied in non-endothelial cell lines.
These data imply expression patterns and roles in
epithelia not previously anticipated for NRP-1.
Butyrate is thought to have chemopreventative proper-
ties in the colon. We have previously shown that at phy-
siologically relevant concentrations in vitro it is a potent
inducer of apoptosis in all the cell lines used [5]. We
and others have shown that up-regulation of the pro-
apoptotic protein Bak occurs in multiple colon cell lines
preceding apoptosis and have proposed this as a major
contributory mechanism of cell death [5,20,21]. The
down-regulation of both VEGF and its receptor NRP-1,
shown in this study, suggest an alternative or contribu-
tory mechanism to colon cell death following butyrate
treatment. The downregulation of NRP-1 is conserved
amongst all three cell lines (see fig 2) following butyrate
treatment. Critically, there is little or no detectable
expression of the principle VEGF receptors in these cell
lines, implicating NRP-1, and possibly NRP-2, as the pri-
mary VEGF receptor and signal transducer. The down-
regulation of NRP-1 is paralleled by the down-regulation
of the ligand VEGF, at least at the mRNA level in two of
the three cell lines. The regulation of VEGF by butyrate
seems more complex as our data suggest that transcrip-
tion and secretion cease faster than the protein is
degraded, leading to an observed increase in intracellu-
lar VEGF. This parallels the multi-tier level of regulation
previously reported in the study of HIF-regulated genes
by butyrate [16]. This may imply a coordinate mechan-
ism of gene regulation, which may have a mechanistic
basis [22]. We noted that although there was a clear
concentration-responsiveness of downregulation of
VEGF by butyrate at the mRNA and secreted protein
levels, there was a trend to increased expression at the
protein level. We hypothesise that this reflects a cessa-
tion of secretion in parallel to downregulation of tran-
scription, but in advance of cessation of translation and
protein degradation. The application of a high-content
analysis approach was used to study the response of
NRP-1 to multiple HDACi. The conservation of NRP-1
downregulation following treatment with multiple
HDACi with distinct activities suggests that the
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Page 8 of 13Figure 6 Butyrate down-regulates VEGF at the mRNA and protein level. Human colon cancer cell lines were treated with increasing
concentrations of butyrate. RNA and protein samples for analysis were described as in fig 2. (A) Butyrate significantly reduced VEGF mRNA
expression compared to untreated cells in HCT116 and Caco-2 cell lines whereas there was no significant difference of VEGF expression in HT29
cells. (B) Supernatants of HCT116 cultures treated with increasing concentrations of butyrate were assessed for VEGF levels by ELISA. (Bi) shows
the absolute quantitation of VEGF, (Bii) shows the VEGF level normalised to cell count. (C) The level of VEGF protein was established in samples
from cells treated with the same range of butyrate concentrations (Ci), shows sample immunoblots of VEGF and actin loading control. Intensity
was quantitated, normalized to actin and expressed as a proportion of the untreated control (Cii). *P < 0.05, **P < 0.01. (D) Levels of VEGF in
cells and at subcellular locations were determined by HCA. The means ± SD of three independent repeat experiments are shown for total VEGF
(subpanel i); perinuclear VEGF (subpanel ii) and cytoplasmic VEGF (subpanel iii). Significance of decrease across three experiments was
determined by ANOVA with p-values inset in the figures. Sample HCA images showing distribution of VEGF in untreated cells (subpanel iv) and
following treatment with 10 mM butyrate (subpanel v). Butyrate treatment resulted in a more punctuate staining pattern (see arrows).
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Page 9 of 13downregulation of NRP-1 is mediated through an acety-
lation-dependent pathway and is not specific to the
enterocytic response to butyrate. These data indicate the
potential of HDACi as a chemotherapeutic route to sup-
pression of NRP-1 dependent chemoresistance and
angiogenesis in the colon.
The downstream signalling pathways of NRP-1 are not
yet well understood although progress is being made in
the dissection of pathways in endothelial cells [23]. We
propose a testable model for the transcriptional regula-
tion of NRP-1 gene, summarized in Fig 7. In this model,
the NRP-1 promoter is competed for by Sp1, Sp3S and
Sp3L. There is a conflicted literature around whether
Sp3L acts as a repressor [24] or transactivator [25,26],
although there is more consensus that Sp3S is a repres-
s o r[ 2 6 , 2 7 ] .O u rd a t af o rB a ks u g g e s tt h a tS p 3 L is a
transactivator in this cell line [5]. In our proposed
model, in the absence of butyrate, Sp1 has greater affi-
nity for the NRP-1 promoter, but weaker transactiva-
tional potential, than Sp3L.S p 3 S acts as a repressor.
Following butyrate treatment all the proteins have the
potential to become acetylated. We have shown that
that acetylation of Sp1 results in reduced DNA binding
affinity [6]. The data in Fig 3 suggest that the affinity of
both Sp1 and Sp3S is reduced following butyrate treat-
ment, which given the constancy of the downregulation
in response to other HDACi (see Fig 4), we propose is
mediated by acetylation. In contrast Sp3L binding is not
reduced by acetylation (see fig 3) but is converted to a
repressor. This model is also compatible with the data
from the siRNA experiment - if Sp1 is knocked down,
the transactivational form of Sp3 has access to the pro-
moter, increasing transcription; likewise if Sp3 is
knocked down, the repressive action of Sp3S is blocked.
We anticipate that further studies of this promoter will
reveal a more complex model, as this proposal, whilst
accommodating all our data, does not yet account for
the higher level interaction with other transctivators
known at the NRP-1 promoter, including AP-1 [14].
As NRP-1 is involved in both angiogenesis and the
prevention of apoptosis in colorectal cancer these data
suggest two potential mechanisms for chemoprevention
- through the apoptotic regulatory function of NRP-1
and through its pro-angiogenic role. The recent findings
that NRP-1 may be expressed in normal epithelia
[9,12,23], indicate a role for it in epithelial biology and
work must be directed at establishing the extent or
otherwise to which endothelial signalling mechanisms
are replicated in epithelia.
Conclusion
Our data therefore suggest routes to improve therapeu-
tic outcome in the colon: through dietary- (or enema-)
mediated alteration in luminal butyrate, or through
development of specific HDACi to the NRP-1/VEGF
pathway. Both of these areas are the subject of our
ongoing study.
Materials and methods
Colon cancer cell line, cell culture and reagent
Caco-2, HCT116 and HT29 human colon cancer cell
lines were kindly donated to Prof C Dive’s group (PICR,
Manchester, UK). The cells were grown in 1 g/L glucose
DMEM (GIBCO) with Penicillin/Streptomycin antibio-
tics and 10% fetal calf serum (Biosera) at 37°C in 5%
CO2, 95% air. Dose response effects of sodium butyrate
(Calbiochem) were detected by treating cells with cul-
ture media supplemented 0 to 20 mM sodium butyrate
for 24 hours. 1M stocks of sodium butyrate were made
up in PBS and diluted in culture media to give the cor-
rect final concentration.
Protein extraction and immunoblotting
Whole cell lysates were collected by resuspending cell
pellets in cell kinase buffer (1M Tris pH5.5, 1M NaF,
1M b-glycerophosphate, 0.2M EDTA, 0.2M EGTA,
10% Triton X-100, 0.1M PMSF, 0.1M NaVO4 and 1×
proteases inhibitor cocktail, Sigma). Protein concentra-
t i o n sw e r em e a s u r e di nt r i p l i c a t eb yB r a d f o r dr e a g e n t
(Bio-Rad), and 20 μg of protein samples were loaded
per well. Transfer membranes were incubated in pri-
mary anti-NRP-1 (1:1000 dilution; Santa Cruz) or anti-
VEGF (1:1000 dilution; Santa Cruz) for 2 hours at
room temperature with gentle agitation, and then in
peroxidase-conjugated goat anti-rabbit IgG (1:2000
dilution; Dakocytomation). The immunoblotting results
were visualized by CHEMI GENIUS Bio imaging sys-
tem. The membranes were washed and re-probed with
anti-human actin antibody (1:10000 dilution; Abcam)
as an equal loading control.
RNA extraction, RT-PCR and quantitative-PCR (q-PCR)
Total RNA was extracted using Trizol reagent (Invitro-
gen) following the manufacturer’s instructions. Reverse
transcription was performed with random primers (Pro-
mega) in 1 μg of total RNA using the Superscript III
Reverse Transcriptase system (Invitrogen). PCR or qPCR
were performed in ReadyMix PCR master mix (Thermo)
or 1× SYBR green reagent (QIAGEN) with 1 μlc D N A .
Forward and reverse primers for RT-PCR (Sigma-
genosys) were designed for amplifying VEGF isoforms
a n dt h e i rr e c e p t o r s ,N R P - 1 ,N R P - 2 ,P D G F A ,P D G F B ,
PDGFRa,P D G F R b,H G F ,H G F Ra n da c t i n( A d d i t i o n a l
file 1: Fig S4). QRT-PCR quantitect assays were pur-
chased from Qiagen for quantitative PCR. QPCR data
were collected on the ABI StepOnePlus platform. Rela-
tive fold changes were calculated using the ΔΔCT
method as previously described [5].
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An adapted version of the EMSA protocol, a western of a
mobility shift gel (WeMSA) was carried out as previously
described [5]. Briefly: unlabelled oligonucleotides were
incubated with nuclear extracts as per Lightshift EMSA
kit instructions; complexes were separated by molecular
weight using 5% TBE acrylamide mini-gels in 0.5 × TBE;
gels were incubated in SDS buffer (25 mM Tris; 192 mM
glycine; 0.2% (w/v) SDS) for 10 min prior to being trans-
ferred to PVDF at 100V for 1 hr in 0.5 × TBE; the mem-
branes were blocked in 5% milk TBST for 1 hr prior to
immunoprobing and ECL detection of HRP conjugated
secondary antibodies. Oligonucleotides for binding assays
were commissioned from Sigma Genosys. Oligonucleo-
tides used for for EMSA were 3’ biotin-labelled.
siRNA transfection
siRNA transfections were carried out using Ambion
NeoFX as per manufacturer’s instructions. Briefly
siRNAs and transfection reagent were diluted in Opti-
MEM (Invitrogen) in two separate tubes. Diluted siRNA
and diluted transfection reagent were then mixed
together and incubated at room temp for ten min. Com-
plexes were transferred to 24 well plates and 0.5 ml
HCT116 cell suspension in antibiotic free media (1 ×
10
4 cells) were added to each well. A final concentration
of 30 nM of siRNA was used. HCT116 cells were trans-
fected with siRNA to Sp1/3 or validated siRNA to
H D A C s1 ,2a n d3 .C o n t r o l su s e dw e r es i R N At o
GAPDH, a proprietary negative control siRNA, and
mock transfected cells. 24 and 48 hours transfection, the
cells were collected for RNA and protein extraction
respectively, followed by qRT-PCR and immunoblotting
analyses.
Enzyme-linked immunosorbent assay (ELISA)
Conditioned media from cultured cells were collected
after each experiment and spun down to remove dead
Figure 7 Model for regulation of NRP-1 expression by Sp transcription factors and HDACs. The model shows the interaction between
Sp1, Sp3S and Sp3L function in the presence and absence of HDAC inhibition and also accounts for the effects of knockdown of Sp1 or Sp3
using the siRNA strategy.
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Page 11 of 13cells and debris. Total VEGF concentration in the cul-
ture media was determined by ELISA according to the
manufacturer’s instruction (R&D system). The degree of
intensity was measured using BioTek microplate reader
at 450 nm optical density with correction at 560 nm.
High Content Analysis (HCA)
Cells were grown for HCA analysis as described above, in
96 well plates. Cells were fixed by 3.5% formaldehyde in
PBS for 15 minutes at room temperature. NRP-1 (R&D
system), acetyl-SP1 (in-house) and VEGF (Abcam) anti-
bodies were diluted in digitonin (500 μl/ml; Sigma) treat-
ing cells for 30 minutes at room temperature. The cells
were then incubated with anti-sheep Alexa Fluor-blue
(Invitrogen) or anti-mouse Alexa Fluor-555 (Invitrogen)
antibodies. DNA was stained with Hoechst at 2.5 μg/ml.
Plates were analysed on a Cellomics Arrayscan. The
Arrayscan compartmental analysis algorithm was used to
generate a mask to measure cell surface and cytoplasmic
staining independently.
Statistical analysis
The results were expressed as mean ± standard error of
the mean (SEM). Densitometric analysis of western blots
was performed by Gene Tool software from SynGene to
quantify the results of western blotting and westerns of
electromobility shift assays. All statisical analyses were
conducted using SPSS v18 software (Chicago, IL, USA)
and Prism 5. Statistical significance was determined
using one-way ANOVA in ELISA and HCA results, and
Student’s t test was used in densitometric and qRT-PCR
results. Each experiment was repeated at least 3 times.
P < 0.05 was considered statistically significant.
Additional material
Additional file 1: Supplementary figures. Fig S1. Pilot data generated
from microarray Fig S2. Additional microscopy images supporting data in
the paper. Fig S3. Data on the subcellular localisation of NRP-1 and VEGF
following butyrate treatment. Fig S4. Detailed description of PCR primers
used.
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